multiple myeloma

Research in Review

Cost-Effectiveness of Multiple Myeloma Therapies From a Payer‚Äôs Perspective

08/02/2017

JCP Editors

A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma, published in the Journal of Managed Care & Specialty Pharmacy (August...

A...

08/02/2017

Journal of Clinical Pathways

Research in Review

Predictor of Aggressive Disease in Multiple Myeloma Identified

07/18/2017

JCP Editors

Certain patients with multiple myeloma often have poorer outcomes, according to a recent meta-analysis. ----- Related Content Circulating tumor cells may help guide bladder cancer treatment Plasma ghrelin levels...

...

07/18/2017

Journal of Clinical Pathways

Research in Review

Triplet Combination Shows Durable Responses in Advanced Multiple Myeloma

07/17/2017

JCP Editors

Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...

...

07/17/2017

Journal of Clinical Pathways

Research in Review

Comparing Prognostic Values of MRI or PET-CT at Multiple Myeloma Diagnosis

07/12/2017

JCP Editors

Researchers identified which imaging technique is better for evaluating prognosis of newly-diagnosed multiple myeloma, published in the Journal of Clinical Oncology (published online July 7, 2017;...

...

07/12/2017

Journal of Clinical Pathways

Research in Review

Triplet Combination Shows Long-Term Efficacy in Advanced Multiple Myeloma

06/26/2017

JCP Editors

Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the...

...

06/26/2017

Journal of Clinical Pathways

Research in Review

Prognostic Tools Identify High-Risk Patients With Multiple Myeloma, Predict Survival

06/22/2017

JCP Editors

Multiple prognostic tools help risk stratify older patients with multiple myeloma and predict treatment-specific survival, according to data that will be presented at the 22nd Congress of the European Hematology...

...

06/22/2017

Journal of Clinical Pathways

Research in Review

CAR T-Cells Improve Outcomes in Multiple Myeloma

06/13/2017

JCP Editors

Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...

...

06/13/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Improves Standard of Care for Multiple Myeloma

06/08/2017

JCP Editors

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...

Adding...

06/08/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy May Improve Outcomes for Patients With Multiple Myeloma

05/22/2017

JCP Editors

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma, according to research that will be presented at the 2017 ASCO...

...

05/22/2017

Journal of Clinical Pathways

Research in Review

Transplantation After High-Dose Chemo Effective in Treating Multiple Myeloma

04/19/2017

JCP Editors

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival (PFS) by 14 months compared with patients who...

Adult...

04/19/2017

Journal of Clinical Pathways